A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis
Céline Louapre, Michèlle Rosenzwajg, Marianne Golse, Anne‐Françoise Roux, Fabien Pitoiset, Leslie Adda, Nicolas Tchitchek, Caroline Papeix, Élisabeth Maillart, Aurelian Ungureanu, Fanny Charbonnier‐Beaupel, Damien Galanaud, Jean‐Christophe Corvol, Éric Vicaut, Catherine Lubetzki, David Klatzmann
Topics & Concepts
MedicineMultiple sclerosisPlaceboInternal medicineNeurologyClinical endpointGastroenterologyRelapsing remittingClinical trialExpanded Disability Status ScaleIL-2 receptorRandomized controlled trialImmunologyImmune systemPathologyT cellAlternative medicinePsychiatryMultiple Sclerosis Research StudiesImmune Response and InflammationVagus Nerve Stimulation Research